This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Loscalzo, J. Articles by Ganz, P. Search for Related Content PubMed PubMed Citation Articles by Loscalzo, J. Articles by Ganz, P.

Circulation, Vol 79, 776-782, Copyright © 1989 by American Heart Association

ARTICLES

Clot-selective coronary thrombolysis with pro-urokinase

J Loscalzo, TP Wharton, JM Kirshenbaum, HJ Levine, JT Flaherty, EJ Topol, K Ramaswamy, BD Kosowsky, DN Salem and P Ganz
Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.

Recognition that myocardial infarction is caused by coronary thrombosis has stimulated a search for a safe, rapidly acting, and effective thrombolytic regimen. Tissue plasminogen activator (t-PA) can provide relatively clot-selective thrombolysis, but one quarter of patients fail to achieve reperfusion, lysis speed is not optimal, and higher doses have been associated with an increased incidence of hemorrhagic stroke. We report the results of a multicenter study of pro-urokinase, a second naturally occurring plasminogen activator that has structural similarities to t-PA but has a different mechanism of action. Pro- urokinase was administered 3.9 +/- 1.1 hours after the onset of chest pain to 40 patients with acute myocardial infarction with angiographically confirmed complete coronary occlusion (TIMI grade 0). After a 90-minute intravenous infusion of pro-urokinase (4.7-9 million units, 36-69 mg) 51% (20 of 39) of the patients demonstrated reperfusion (TIMI grade 2 or 3) occurring 64.8 +/- 22.3 minutes after initiation of therapy. Fibrinogen levels fell only 10 +/- 17% from baseline, confirming the fibrin specificity of pro-urokinase. As with t- PA, however, this specificity was only relative. alpha 2-Antiplasmin decreased to 39% and plasminogen decreased to 64% of initial values. Fibrinogen degradation products increased 63% and the fibrin-specific D- dimer increased 8.7-fold. Thus, pro-urokinase produces relatively clot- selective coronary thrombolysis similar to that produced by t-PA, but the use of either pro-urokinase or t-PA alone in higher doses would be likely to produce more nonspecific effects.

This article has been cited by other articles:

				PRO-UROKINASE: A CLOT-SELECTIVE THROMBOLYTIC AGENT? Journal Watch (General), April 21, 1989; 1989(421): 4 - 4. [Full Text]